Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mechanism established in the single-dose cohorts. The study of nadunolimab in triple-negative breast cancer has been delayed by up to six months with readout now expected by H1 2025.
LÄS MER